These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt||2011-000033-36||A phase I/II study of 177Lu-HH1 (Betalutin®) radioimmunotherapy for treatment of relapsed non-Hodgkin lymphoma||not-yet-due|
|Not reported||2015-001570-17||A Phase 2 study of the antibody-radionuclide-conjugate 177Lu-DOTA-HH1 (Betalutin™) in patients with CD37-positive relapsed follicular lymphoma||2015-12-09||due-trials|
|Ongoing||2017-004506-18||A phase 2 open-label study of Betalutin in combination with rituximab in patients with relapsed/refractory follicular lymphoma (Archer-1)||not-yet-due|